Join OBI and colleagues for Accelerate Happy Hour from 5:30 to 7:00pm. Connect with fellow biotech and digital health professionals, build community, and share ideas to accelerate the growth of these sectors in Portland.
Accelerate Happy Hours bring together passionate professionals in biotech, medical devices, and digital health across academia and industry. This is your chance to network and build relationships with others working in these fields. July's Happy Hour is sponsored by Genentech.
Interested in introducing your startup or idea? We offer 2-minute speaking slots at each event. To reserve a spot, email us at aklein@otradi.org.
OBI is located at:
4640 S Macadam Ave, Suite 240
Portland, OR 97239
There is no cost to attend but registration is required. Register here!
Event
AOBIO 2025 Fall Education Program
Location
Online/Zoom
Angel Oregon Life & Bioscience (AOBIO) is designed to support early-stage life and bioscience startups based in Oregon and Southwest Washington by offering investment-readiness education, connectivity within the local bioscience community, and the opportunity to receive an equity investment from local angel investors.
Like the in the Spring 2025 program, the September cohort will particiipate in an online three-week investment-readiness series for life and bioscience startups at any stage of development. Courses take place on Thursdays from 8:30 to 10:00am and will cover:
September 4: Capital Readiness for Bio Startups
September 11: Valuations and Cap Tables for Bio Startups
September 18: Due Diligence for Bio Startups
In addition, the program will include an in-person pitch practice at OBI/OTRADI on Thursday, September 25 from from 11am to 1pm with feedback from regional thought leaders.
FDA Programs to Facilitate and Expedite Development of New Drugs
Location
Online/Zoom
Join Dr. Elizabeth Gordon from 12 to 1pm for an engaging and informative Virtual Lunch & Learn series, where we will dive deep into the key aspects of drug development in the U.S. This is the last installment of our 3-part series designed to provide a comprehensive understanding of the critical steps, strategies, and regulatory considerations that drive successful pharmaceutical product development.
This session will present the mechanisms that exist to expedite approval of products to treat life-threatening diseases and conditions. The goal of these programs is to accelerate the availability of new therapies to patients with serious conditions, especially when there are no satisfactory alternatives. The benefits of each program will be reviewed, and the data requirements for successful application will be discussed.